Active Ingredient History
Omaveloxolone is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development by Reata Pharmaceuticals. Preclinical studies have demonstrated that omaveloxolone possesses antioxidative and anti-inflammatory activities and the ability to improve mitochondrial bioenergetics. Omaveloxolone is currently under clinical investigation for a variety of indications, including Friedreich’s ataxia, mitochondrial myopathies, immunooncology, and prevention of corneal endothelial cell loss following cataract surgery. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Corneal Endothelial Cell Loss (Phase 2)
Friedreich Ataxia (Phase 2)
General Surgery (Phase 2)
Healthy Volunteers (Phase 1)
Inflammation (Phase 2)
Liver Diseases (Phase 1)
Melanoma (Phase 2)
Mitochondrial Myopathies (Phase 2)
Pain (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue